Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies
Figure 2
Comparison of the cellular and molecular immune environment of a B cell murine lymphoma implanted in the spleen, in the brain or in the eye. (a) A20.IIA-GFP cells were implanted in immunocompetent syngeneic mice in the spleen (intrasplenic lymphoma model: ISL), in the brain (primary intracerebral lymphoma model: PCL), or in the eye (primary intraocular lymphoma model: PIOL). 21 days after injection, tumor-bearing organs were analyzed by flow cytometry for the presence of GFP+ tumor cells, CD3+ T lymphocytes, NKp46+ NK cells, Gr1+ neutrophils, CD11c+ dendritic cells, and CD11b+CD11c− macrophages. Results are represented as the proportion of the different populations among total living cells (). (b) 21 days after lymphoma (gray boxes) or PBS (white boxes) injection, cells were isolated from appropriate tissues and stimulated for 36 h with anti-CD3/CD28-coated Dynal beads. Secretion of IL-2, IFNγ, GM-CSF, IL-4, IL-10, and IL-17 in the culture supernatant was evaluated by cytokine bead arrays (BD Biosciences) (). Animal studies were conformed to European Union guidelines and were approved by the Charles Darwin Ethics Committee in Animal Experiment, Paris, France.
